Why the study?
Does short-term high-dose atorvastatin plus N-acetylcysteine prevent contrast-induced nephropathy in patients undergoing coronary angiography?
Does short-term high-dose atorvastatin plus N-acetylcysteine prevent contrast-induced nephropathy in patients undergoing coronary angiography?
Short-term high-dose atorvastatin added to NAC significantly improves post-procedural creatinine and eGFR compared to NAC alone, though it did not significantly reduce the incidence of contrast-induced nephropathy in this small cohort.
No takes yet. Share an insight, caveat, or question.
May improve renal markers without reducing CIN incidence; hypothesis-generating and should not yet change practice.
Özhan et al. (2010) studied this question.